Search
USFDA Request for Information: AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program
Artificial Intelligence (AI) is rapidly transforming drug development by enabling more efficient data analysis, predictive modelling, and evidence-based decision-making. Early-phase clinical trials, particularly Phase 1 studies, represent one of the most challenging stages of drug development due to uncertainties surrounding dose selection, patient recruitment, safety monitoring, and progression decisions. Improving the efficiency of these trials has the potential to accelera
Sharan Murugan
6 hours ago4 min read